Biotech catalyst calendar
Clinical trials led by listed companies, by the completion date the sponsor registered on ClinicalTrials.gov, soonest first, from today. Most future dates are the sponsor's estimate and can move.
- Completion LockedPhase 3NCT04634877Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly...Merck Sharp & Dohme LLC · Endometrial NeoplasmsActive, not recruitingMRKLead
- Enrollment
- Locked
- Primary completion
- Nov 20, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 3NCT05261399Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have...AstraZeneca · CarcinomaActive, not recruitingAZNLead
- Enrollment
- Locked
- Primary completion
- Jul 6, 2026Actual
- Interventions
- Locked
- Completion LockedPhase 3NCT06693895A Study on the Safety of an Investigational Chickenpox Vaccine, When Given to Healthy Children, 12 to 15 Months of AgeGlaxoSmithKline · ChickenpoxRecruitingGSKLead
- Enrollment
- Locked
- Primary completion
- Nov 23, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 3NCT07216079Rilzabrutinib for the Adult Participants With Chronic ITP Who Have Completed Phase 3 Study in JapanSanofi · Immune ThrombocytopeniaActive, not recruitingSNYLead
- Enrollment
- Locked
- Primary completion
- Nov 25, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 3NCT03981796A Study to Evaluate Dostarlimab Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Participants With Recurrent or...Tesaro, Inc. · NeoplasmsActive, not recruitingGSKLead
- Enrollment
- Locked
- Primary completion
- Nov 26, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 3NCT04099251Effectiveness Study of Nivolumab Compared to Placebo in Prevention of Recurrent Melanoma After Complete Resection of Stage IIB/C MelanomaBristol-Myers Squibb · MelanomaActive, not recruitingBMYLead
- Enrollment
- Locked
- Primary completion
- Jun 28, 2022Actual
- Interventions
- Locked
- Completion LockedPhase 3NCT04157348Efficacy and Safety of Benralizumab in EGPA Compared to Mepolizumab.AstraZeneca · Eosinophilic Granulomatous VasculitisActive, not recruitingAZNLead
- Enrollment
- Locked
- Primary completion
- Aug 10, 2023Actual
- Interventions
- Locked
- Completion LockedPhase 3NCT06734832Efficacy, Safety, and Immunogenicity of the Bivalent Inactivated Enterovirus Vaccine (Vero Cell)Sinovac Biotech Co., Ltd · Hand, Foot, and Mouth Disease(HFMD)RecruitingSVALead
- Enrollment
- Locked
- Primary completion
- Nov 30, 2025Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 3NCT06838000Study of the Safety and Immunogenicity of Catch-up Vaccination With a 21-valent Pneumococcal Conjugate Vaccine (PCV21) in Healthy...Sanofi Pasteur, a Sanofi Company · Pneumococcal InfectionsActive, not recruitingSNYLead
- Enrollment
- Locked
- Primary completion
- Dec 1, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 3NCT07446439A Study to Evaluate Tradipitant on Treating Nausea and Vomiting Induced by GLP-1R Agonist UseVanda Pharmaceuticals · Nausea and VomitingRecruitingVNDALead
- Enrollment
- Locked
- Primary completion
- Dec 1, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 3NCT04165317A Study of Sasanlimab in People With Non-muscle Invasive Bladder CancerPfizer · Non-muscle Invasive Bladder CancerActive, not recruitingPFELead
- Enrollment
- Locked
- Primary completion
- Dec 2, 2024Actual
- Interventions
- Locked
- Completion LockedPhase 3NCT07500506A Study to Learn About the Safety, Tolerability, and Immunogenicity of a Fifth Dose of 6-Valent OspA-Based Lyme Disease VaccinePfizer · Lyme DiseaseRecruitingPFELead
- Enrollment
- Locked
- Primary completion
- Dec 4, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 3NCT05726227A Research Study on How Well Semaglutide Helps Children and Teenagers With Excess Body Weight Lose WeightNovo Nordisk A/S · ObesityActive, not recruitingNVOLead
- Enrollment
- Locked
- Primary completion
- Oct 15, 2025Actual
- Interventions
- Locked
- Completion LockedPhase 3NCT06724809Efficacy, Safety, PK, PD, and ADA of Eculizumab in Chinese Adults With NMOSDAlexion Pharmaceuticals, Inc. · NMOSDActive, not recruitingAZNLead
- Enrollment
- Locked
- Primary completion
- Dec 7, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 3NCT05757869A Study of Milvexian Versus Apixaban in Participants With Atrial FibrillationJanssen Research & Development, LLC · Atrial FibrillationActive, not recruitingJNJLeadBMYCollaborator
- Enrollment
- Locked
- Primary completion
- Dec 8, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 3NCT06126224A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-2)Karuna Therapeutics, Inc., a Bristol Myers Squibb company · Psychosis Associated With Alzheimer's DiseaseRecruitingBMYLead
- Enrollment
- Locked
- Primary completion
- Dec 9, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 3NCT06430866Pharmacokinetic Similarity Between ABP 234 and Keytruda® (Pembrolizumab)Amgen · Early-stage Non-squamous Non-small Cell Lung Cancer (NSCLC)Active, not recruitingAMGNLead
- Enrollment
- Locked
- Primary completion
- Dec 14, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 3NCT06625398An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants With Chronic Thyroid Eye Disease (TED)Viridian Therapeutics, Inc. · Thyroid Eye DiseaseActive, not recruitingVRDNLead
- Enrollment
- Locked
- Primary completion
- Mar 4, 2026Actual
- Interventions
- Locked
- Completion LockedPhase 3NCT06245408A Safety and Efficacy Study of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-Severe Symptom StateAmgen · Sjögren's Syndrome (SS)Active, not recruitingAMGNLead
- Enrollment
- Locked
- Primary completion
- Oct 22, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 3NCT07363720A Trial of TAK-861 for the Treatment of Narcolepsy With CataplexyTakeda · Narcolepsy Type 1 (NT1)Active, not recruitingTAKLead
- Enrollment
- Locked
- Primary completion
- Dec 17, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 3NCT03451851A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Subcutaneously Administered Guselkumab for the Treatment of Chronic...Janssen Research & Development, LLC · PsoriasisActive, not recruitingJNJLead
- Enrollment
- Locked
- Primary completion
- Jul 19, 2023Actual
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 21 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScannerHow to read this calendar
Completion dates as registered on ClinicalTrials.gov by the sponsor, for trials Signal8 links to a listed company. Most future dates are the sponsor's estimate and move. A completion date is when the last participant is measured, not when results are announced.
The window starts today. A date the sponsor registered to the day is listed when it falls inside the window; a date that has already passed is never listed as upcoming, even when the sponsor has not updated it yet. A date registered to the month only (shown as, say, Dec 2026) could be any day of that month, so it is listed only when the whole month falls inside the window. TrialScanner never adds a day the sponsor did not register.
By default the list shows trials where a listed company is the lead sponsor. Trials a listed company only collaborates on (as a partner, drug supplier or contract research organization) are added with the role filter, and every company is labelled Lead or Collaborator.
Free readers see the first 25 trials of any filter and windows up to 90 days, with the trial, phase, status, sponsor and primary completion. Enrollment, interventions, the start and completion dates, longer windows and later pages are part of the plan. See the methodology.